Recent Company News

• 12:00 AM ET Aug 28, 2026
  

  Clinuvel Pharmaceuticals downgraded to hold from speculative buy at Morgans (timing uncertain) (A$8.41, -0.77)

• 09:40 PM ET Aug 27, 2026
  

  StreetAccount Summary - Trading higher/lower: Australia & New Zealand midday

• 06:09 PM ET Aug 27, 2026
  

  Clinuvel Pharmaceuticals downgraded to speculative hold from buy at Bell Potter (A$9.18, 0.00)

• 05:30 PM ET Aug 27, 2026
  

  Clinuvel Pharmaceuticals downgraded to hold from buy at Canaccord Genuity (A$9.18, 0.00)

• 07:27 AM ET Aug 27, 2026
  

  Transcript Intelligence: Clinuvel Pharmaceuticals Q4 Earnings Guidance

• 07:26 AM ET Aug 27, 2026
  

  Transcript Intelligence: Clinuvel Pharmaceuticals Q4 Earnings Themes

• 07:26 AM ET Aug 27, 2026
  

  Transcript Intelligence: Clinuvel Pharmaceuticals Q4 Earnings Q&A

• 10:25 PM ET Aug 26, 2026
  

  Clinuvel Pharmaceuticals reports FY NPAT A$33.9M vs FactSet A$35.2M [5 est, A$29.8-40.1M] (A$10.69, +0.17)

• 07:14 PM ET Aug 11, 2026
  

  Clinuvel Pharmaceuticals advancing controlled-release injectable liquid peptide platform VLRX-L (A$9.71, 0.00)

• 06:59 PM ET Jul 27, 2026
  

  Clinuvel Pharmaceuticals provides updates on SCENESSE in vitiligo; SCENESSE and adjuvant narrowband UVB to be evaluated (A$9.81, 0.00)